Anti-topoisomerase II α autoantibodies in systemic sclerosis - Association with pulmonary hypertension and HLA-B35

Clinical and Experimental Immunology

Volumn 121, Issue 3, 2000, Pages 539-543

  Grigolo, B ^a   Mazzetti, I ^a   Meliconi, R ^b   Bazzi, S ^c   Scorza, R ^c   Candela, M ^d   Gabrielli, A ^d   Facchini, A ^a,b  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Anti topoisomerase II ; Pulmonary hypertension; Systemic sclerosis

Indexed keywords

AUTOANTIBODY; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; HLA B35 ANTIGEN;

ADULT; ANTIBODY DETECTION; ANTIBODY PRODUCTION; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; LUNG FIBROSIS; MALE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SCLEROSIS;

ADULT; ALLELES; AUTOANTIBODIES; CASE-CONTROL STUDIES; DNA TOPOISOMERASES, TYPE II; FEMALE; HLA-B35 ANTIGEN; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 0033850582     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.2000.01320.x     Document Type: Article

References (45)

1. Systemic sclerosis (scleroderma): Clinical aspects
2. Identification of a nuclear protein (Scl-70) as a major target of human antinuclear antibodies in Scleroderma
3. High titer of autoantibodies to Topoisomerase I (Scl-70) in sera from scleroderma patients
4. Identification of a subset of patients with scleroderma with severe pulmonary and vascular disease by the presence of autoantibodies to centromere and hystone
5. Autoantibody reactive with RNA polymerase III in systemic sclerosis
6. Autoantibody reactive with three classes of the RNA polymerases in sera from patients with systemic sclerosis
7. Identification of autoantibodies to the I protein of the heterogenous nuclear ribonucleoprotein complex in patients with systemic sclerosis
8. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis
9. HLA and clinical associations in systemic sclerosis patients with anti-Th/To antibodies
10. Autoantibodies to fibrillarin in systemic sclerosis (scleroderma)
11. Systemic sclerosis: An autoantibody mosaic
12. Lung involvement in systemic sclerosis (scleroderma): Relation to classification based on extent of skin involvement or autoantibody status
13. Autoantibodies to DNA topoisomerase II in cryptogenic fibrosing alveolitis and connective tissue disease
14. Antibodies to topoisomerase II α in idiopathic pulmonary fibrosis
15. Autoantibodies to DNA topoisomerase II in juvenile rheumatoid arthritis
16. Characterization of human DNA topoisomerase II as an autoantigen recognized by patients with IDDM
17. Human autoantibody to topoisomerase II
18. Preliminary criteria for the classification of systemic sclerosis (scleroderma)
19. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis
20. Continuous wave Doppler determination of right ventricular pressure: A simultaneous Dopplercatheterization study in 127 patients
21. Comparison of different methods for the detection of autoantibodies in autoimmune diseases
22. Antinuclear antibodies in progressive systemic sclerosis
23. Microdroplet testing for HLA-A-B-C, and -D antigens
24. Major histocompatibility complexes class II and C4 alleles in Mexican Americans with systemic lupus erythematosus
25. DNA topoisomerases: Enzymes that catalyze the breaking and rejoining of DNA
26. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: The target of the drugs in DNA
27. Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxin in Simian virus 40-infected monkey cells
28. Mechanism of antitumor drug action: Poisoning of mammalian topoisomerse II on DNA by m-AMSA
29. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer treated with topoisomerase II-interactive antitumor drugs
30. Altered DNA ligase I activity in Bloom's syndrome cells
31. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle
32. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II
33. Monoclonal antibodies to human DNA topoisomerase I. and the two isoforms of DNA topoisomerase II: 170 and 180-KDa Isozymes
34. Antihistone antibodies in systemic sclerosis. Association with pulmonary fibrosis
35. Lack of association between antihistone antibodies and pulmonary fibrosis in patients with systemic sclerosis: Comment on the article by Sato et al
36. Autoantibody to centromere (kinetochore) in scleroderma sera
37. Mapping of topoisomerase II α epitopes recognized by autoantibodies in idiopathic pulmonary fibrosis
38. Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody
39. Primary pulmonary hypertension, tissue plasminogen activator antibodies, and HLA-DQ7
40. Human immunodeficiency virus infection and pulmonary hypertension: Two new cases and a review of 86 reported cases
41. Primary pulmonary hypertension in a patient with HIV infection
42. Genetics and immunogenetic aspects of primary pulmonary hypertension
43. Primary pulmonary hypertension in HIV infection: An outcome determined by particular HLA class II alleles
44. Determination of an epitope of the diffuse systemic sclerosis marker antigen DNA topoisomerase I. Sequence similarity with retroviral p30(gag) protein suggests a possible cause for autoimmunity in systemic sclerosis